Schroer John R. sold $5K of ALMS

Schroer John R. (Chief Financial Officer) sold 794 shares of ALUMIS INC. (ALMS) at $6.52 on 2026-11-02.

Original reporting
SEC EDGAR · Schroer John R.
Published Nov 4, 2026, 9:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALMS
Bearish
medium confidence
Mentioned
$ALMS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSBearishLow
01

Why it matters

The CFO's modest sale is unlikely to move the stock significantly but may signal slight confidence concerns.

02

Market read

A small insider sale with limited market impact; primarily of interest to current shareholders and short‑term traders monitoring insider activity.

03

What to watch

Potential tax planning or diversification motives unrelated to company fundamentals.

Relevance 3/10Novelty 3/10Timing: today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources of corporate insider activity.

Company-level read

Ticker impact

$ALMSBearishMedium confidence
Context

CFO John R. Schroer sold 794 shares of Alumis Inc. for $5,176.88 on 2026-11-02.

Expected impact

likely slight downward pressure as market prices the insider sale.

Evidence & confidence

The sale is small relative to total holdings and market cap, so impact is limited.

Market effects

None; the transaction is company‑specific.

No broader regional effect.

Minimal; only relevant to Alumis shareholders.

Counterpoint

The sale may be routine and not indicative of future performance.

Key entities

  • Alumis Inc.

    US‑listed provider of cloud‑based construction management software.

  • John R. Schroer

    Chief Financial Officer of Alumis Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALMSMed

Alumis Reports Q3 2026 Results, $94.9 Million Net Loss

Alumis reported Q3 2026 revenue of $1.9M and a net loss of $94.9M. Cash reserves totaled $431.3M, expected to last into Q4 2027. The company plans to submit an NDA for envudeucitinib in plaque psoriasis by Q4 2026, with positive Phase 3 data for scalp psoriasis. A Phase 2b trial in lupus did not meet primary endpoints, but a subgroup showed responses. Alumis will start a Phase 2 trial for A-005 in Parkinson's in 2027.

$ALMSHigh

Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates

ALUMIS INC. (ALMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Exhibit 99.1 ​ ​ Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates ​ – New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib’s differentiated clinical profile, including the hig

$ALMSHighAI 8/10

Alumis (ALMS) Faces Pressure After Clinical Results

Voya MI Dynamic Small Cap Fund reported that its overweight position in Alumis (ALMS) hurt performance due to disappointing clinical trial results. ALMS closed at $6.62 with a $883.74M market cap, up 25.38% over 52 weeks. The fund's Q3 2026 letter cited sector performance variations, with energy, tech, and healthcare outperforming.